Pharma - HealthQuill

US drug regulator clears Qnovia’s nicotine inhaler for clinical testing

HQ Team October 7, 2024: The US Food and Drug Administration (FDA)has cleared Qnovia Inc’s nicotine inhaler RespiRx for clinical trial. The US.

by HealthQuill
October 7, 2024
0 Comments

More than 200 people were murdered worldwide last year while trying to protect their lands and the environment from corporations, governments and non-state actors, according to a Global Witness report.

Climate Health Pharma

More than 200 land defenders died globally in 2023, Colombia deadliest

More than 200 people were murdered worldwide last year while trying to protect their lands and the environment from corporations, governments and non-state.

by HealthQuill
October 6, 2024
0 Comments

Johnson & Johnson has discontinued its mid-stage trial, evaluating an antiviral drug, mosnodenvir, for the prevention of dengue.

Drugs Health Pharma

Johnson & Johnson stops mid-stage trial of drug for dengue prevention

Johnson & Johnson has discontinued its mid-stage trial, evaluating an antiviral drug, mosnodenvir, for the prevention of dengue.

by HealthQuill
October 5, 2024
0 Comments

Italy’s Recordati will acquire global rights for Sanofi’s drug Enjaymo, used in the treatment of a rare autoimmune disease that causes the body's immune system to attack red blood cells, for an upfront $825 million.

Drugs Health Pharma

Recordati buys Sanofi’s drug for autoimmune disease for $825 million

Italy’s Recordati will acquire global rights for Sanofi’s drug Enjaymo, used in the treatment of a rare autoimmune disease that causes the body's.

by HealthQuill
October 5, 2024
0 Comments

Novo Nordisk will invest 864 million reais ($158 million) to revamp its Brazil unit, which accounts for 25% of the drugmaker’s insulin shipments globally.

Climate Drugs Pharma

Denmark’s Novo Nordisk to invest $158 million in Brazil insulin facility

Novo Nordisk will invest 864 million reais ($158 million) to revamp its Brazil unit, which accounts for 25% of the drugmaker’s insulin shipments.

by HealthQuill
October 5, 2024
0 Comments

The European Medicines Agency is reviewing two medicines meant to treat hair loss and prostate enlargement following concerns regarding suicidal ideation and behaviours.

Drugs Health Pharma

EMA starts review of medicines to treat hair loss, prostate enlargement

The European Medicines Agency is reviewing two medicines meant to treat hair loss and prostate enlargement following concerns regarding suicidal ideation and behaviours.

by HealthQuill
October 5, 2024
0 Comments

Drugs Health Pharma

UK scientists receive funding to develop world’s first ovarian cancer vaccine

HQ Team October 4, 2024: Researchers at the University of Oxford have received £600,000 (€719,960) from Cancer Research UK to fund their project.

by HealthQuill
October 4, 2024
0 Comments

British-Swedish AstraZeneca’s drug for treatment of a form of blood cancer has been granted a Priority Review in the US by the drug regulator.

Drugs Health Pharma

AstraZeneca’s experimental blood cancer drug gets US priority review

British-Swedish AstraZeneca’s drug for treatment of a form of blood cancer has been granted a Priority Review in the US by the drug.

by HealthQuill
October 3, 2024
0 Comments

Gilead Sciences, Inc. has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical makers to make and sell its generic lenacapavir drug for the prevention of HIV.

Drugs Health Pharma

Gilead signs six global pacts to make, sell generic HIV preventive drug

Gilead Sciences, Inc. has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical makers to make and sell its generic lenacapavir drug for the prevention.